Doxorubicin-Teva 20 mg/10 ml, injection solution

( ARTG ) Doxorubicin has been used successfully to produce regression in neoplastic conditions such as: acute leukaemia, Wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both Hodgkin's and non-Hodgkin's type, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas, ovarian carcinoma, etc. The main antitumour activities are listed in Table 1 of the Product Information. Doxorubicin is also indicated by intravesical administration in the primary management of non-metastatic carcinoma of the bladder. (Tis, T1, T2).